GLPwatch
Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease.
Annu Rev Med · 2026
Last updated 2026-05-28GLP-1 receptor agonists, initially used for diabetes and later for weight management, have shown strong benefits for heart disease, kidney disease, and a specific type of heart failure called HFpEF. Research and clinical trials have highlighted their protective effects on the cardiovascular system.
AI summary of the abstract below.
| Journal | Annu Rev Med, 2026 |
|---|---|
| Citations | 1 |
| Molecules | — |
| Conditions studied | Cardiovascular Risk Reduction |
Abstract
Glucagon-like peptide 1 receptor (GLP-1R) agonists were originally developed as treatments for diabetes and subsequently evolved into weight management medications. These drugs have recently been shown to demonstrate remarkable efficacy in cardiovascular disease, kidney disease, and heart failure with preserved ejection fraction (HFpEF). In this review, we focus on the cardiovascular protective effects of GLP-1R agonists identified from basic studies and outcome trials, including a brief description of those forthcoming soon.
Verbatim abstract via PubMed 41160742 ↗